Paclitaxel Stents Safe in STEMI

The Harmonising Outcomes with Revascularisation and Stents in Acute Myocardial Infarction (HORIZONS-AMI) was a prospective open label, multi-centre controlled trial involving patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). It incorporated two factorial randomised phases to allow a comparison of the direct thrombin inhibitor bivalirudin alone with heparin plus glycoprotein IIb-IIIa […]

Read More…

Normalisation of blood glucose levels following myocardial infarction predicts favourable in hospital outcome.

Despite a strong association between elevated blood glucose levels and increased rates of mortality among patients hospitalised with acute myocardial infarction (AMI), the benefit of acutely lowering levels of blood glucose remains controversial. Several questions remain unanswered: […]

Read More…

Clopidogrel and Asprin ACTIVEly prevent stroke

The ACTIVE Trial (Atrial Fibrillation Clopidogrel Trial with Irbesartan for the Prevention of Vascular Events) was designed to assess the role of clopidogrel and aspirin in the prevention of stroke and other vascular events in patients with atrial fibrillation (AF). ACTIVE W has already reported and compared clopidogrel + aspirin with a vitamin K antagonist. […]

Read More…

Angiotensin receptor blockers and atrial fibrillation

The recurrence of atrial fibrillation (AF) after cardioversion may be partially related to a process known as remodeling – the electrical, mechanical and structural properties of the atrial tissue are altered in a progressive and irreversible manner resulting in a more favourable substrate for AF. From animal models, blockade of the rennin-angiotensin-aldosterone system (RAAS) has […]

Read More…

ICD implant risks highlight increasing sub-specialisation

Should cardiologists who are not electrophysiologists be inserting implantable cardioverter-defibrillators (ICDs)? Curtis et al. performed a retrospective cohort study of patients who had an ICD fitted between January 2006 and June 2007. Patients were grouped according to whom had implanted their device: electrophysiologists, nonelectrophysiologist cardiologists, thoracic surgeons, and other specialists. The main outcome measures examined […]

Read More…

No benefit from screening asymptomatic type 2 diabetics for CAD

Should patients with type 2 diabetes be screened for coronary artery disease if asymptomatic? In the DIAD study (Detection of Ischemia in Asymptomatic Diabetics), 1123 patients with type 2 diabetes and no symptoms of coronary artery disease (CAD) were randomly assigned to be screened with adenosine-stress myocardial perfusion imaging (MPI) or to no screening. The […]

Read More…

Polypill pushes on

It has been calculated that a polypill containing asprin, a beta-blocker, a statin and an angotensin-converting enzyme inhibitor could reduce cardiovascular events in people with cardiovascular disease by about 75%. It has further been suggested that the addition of folic acid, and the use of three separate agents to lower blood pressure (each in low […]

Read More…